Specialized Working Group on Myelodysplastic Syndromes (MDS)

Overview

The Scientific Working Group (SWG) on Myelodysplastic Syndromes (MDS) is dedicated to promoting and facilitating the exchange of scientific and clinical knowledge, ideas, and collaborative projects in the field of MDS.

Our activities focus on strengthening collaboration among clinicians across Europe, particularly through the development of joint clinical studies and translational research. We do this through the organisation of regular meetings, workshops, and collaborative forums.

Key responsibilities

• The review and, where necessary, revision of existing MDS guidelines to reflect emerging evidence and evolving clinical practice.
• Supporting the translational research community by providing a platform for clinicians and scientists to share the latest advancements in the field and to foster interdisciplinary collaboration.

Aims of the SWG

• To promote collaborative clinical and translational research in MDS across Europe and beyond.
• To provide a platform for the exchange of scientific knowledge and innovative ideas among clinicians, researchers, and stakeholders in MDS.
• To review, update, and disseminate evidence-based clinical guidelines for the diagnosis and management of MDS.
• To support education and training initiatives that build capacity in MDS research and clinical care.
• To foster international partnerships that advance biomarker discovery, personalised medicine, and novel therapeutic approaches in MDS.

International Integrative Innovative Immunology for MDS (i4MDS) consortium

As part of our mission, we’ve launched the International Integrative Innovative Immunology for MDS initiative.

‘i4MDS,’ as it’s generally known, is an international consortium aims to advance the understanding and treatment of MDS through cutting-edge immunological approaches.

With the backing of the SWG, the i4MDS consortium is working collaboratively to design immune-monitoring strategies at the clinical level and to integrate validated immune signatures into MDS risk stratification. Engagement with international experts will enhance our understanding of the immunopathogenic mechanisms driving MDS, thereby facilitating the development of targeted therapies and accelerating the translation of discoveries into clinical benefit.

Join us

If you work in our field and share our mission to advance our understanding of MDS, you’d be welcome to join our SWG. However, before you apply, we recommend you read our application guidance.

Ready? Apply now on the EHA Portal.

If you have any questions, please email our SWGs team.